 |
|
|
|
May 2001 Cover
|
|
A Food and Drug Administration (FDA) advisory committee unanimously voted in favor of Hoffmann-La Roche's new drug to treat cytomegalovirus (CMV) retinitis in AIDS patients. The drug, valganciclovir, is an
oral formulation of Roche's intravenous CMV drug, ganciclovir. FDA advisors recommended approval of the new drug based on tests showing its efficacy in the early stages of the disease; however, the panel did
question valganciclovir's effectiveness over the long-term for the treatment of CMV retinitis in AIDS patients.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
